Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Internal Medicine | Emergency Medicine | Journal

Back to Journal Articles

Higher Bleed Risk in Women With Acute Coronary Syndrome

Last Updated: May 18, 2009.

 

Bivalirudin monotherapy linked to less major bleeding in women with acute coronary syndrome

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Women with acute coronary syndrome gained similar protection against ischemic events with bivalirudin compared to heparin plus a glycoprotein IIb/IIIa inhibitor, with less bleeding, according to research published in the May 1 issue of the American Journal of Cardiology.

MONDAY, May 18 (HealthDay News) -- Women with acute coronary syndrome (ACS) gained similar protection against ischemic events with bivalirudin compared to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI), with less bleeding, according to research published in the May 1 issue of the American Journal of Cardiology.

Alexandra J. Lansky, M.D., of the Columbia University Medical Center and Cardiovascular Research Foundation in New York City, and colleagues analyzed data from 13,819 patients with moderate or high-risk non-ST-elevation ACS. Patients were randomized to receive heparin plus a GPI, bivalirudin and a GPI, or bivalirudin only.

The researchers found that 30-day composite ischemia was similar in men and women. Women had higher 30-day rates of major bleeding (8 versus 3 percent) and net clinical outcomes, which included composite ischemia -- defined as death, myocardial infarction, or revascularization -- or bleeding (13 versus 10 percent). Women on bivalirudin had less 30-day major bleeding (5 versus 10 percent) but similar composite ischemia compared with those on heparin and a GPI, the authors note.

"Our study demonstrated that women presenting with ACS had more chronic kidney disease, diabetes, and hypertension, but had significantly less extensive and complex coronary artery disease, smaller vessels, better coronary flow, and myocardial perfusion than men. These factors likely account for the lower baseline cardiac markers and enzyme release observed in women and similar rates of mortality and ischemic events compared with men observed with all treatment strategies in this study," the authors conclude.

The trial that generated this study was sponsored by The Medicines Company.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Swine Flu Has Higher Fatality Rate Than Seasonal Flu Next: Facial Fractures in Car Accidents Decreasing

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.